Genetix Biotherapeutics Inc.
BiotechGenetix Biotherapeutics Inc. is a biotechnology company with 3 FDA-approved products.
Genetix Biotherapeutics Inc. at a Glance
- Strong track record with 81% execution quality across 8 trials
Genetix Biotherapeutics Inc.'s Key Drugs
Genetix Biotherapeutics Inc.'s core commercial portfolio centers on Zynteglo, Skysona, LYFGENIA — its most strategically important drugs approved in the last 15 years.
Genetix Biotherapeutics Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Genetix Biotherapeutics Inc. over the last two years — novel drugs only, excluding generics and label supplements.
Genetix Biotherapeutics Inc.'s Therapeutic Areas
Disease areas where Genetix Biotherapeutics Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Genetix Biotherapeutics Inc. Pipeline Snapshot
Active clinical trials for Genetix Biotherapeutics Inc. across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Zynteglo leads revenue
- • 3 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/4 completed
- • Speed: 69 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges